PA Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

PA Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$746K	Buy	7,658 +2,322	+44%	+$290K	0.52%	66
2020 Q2	$833K	Sell	5,336 -202	-4%	-$30.7K	0.6%	61
2020 Q1	$799K	Buy	5,538 +1,654	+43%	+$319K	0.71%	59
2019 Q4	$794K	Buy	3,884 +42	+1%	+$7.66K	0.7%	54
2019 Q3	$308K	Sell	3,842 -3,354	-47%	-$285K	0.3%	99
2019 Q2	$679K	Sell	7,196 -2,675	-27%	-$231K	0.62%	60
2019 Q1	$844K	Sell	9,871 -3,915	-28%	-$325K	0.75%	44
2018 Q4	$773K	Buy	+13,786	New	+$842K	0.82%	42

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

PA Capital's RETA Position: Q3 2020 in Review

PA Capital increased its Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) stake by 44% in Q3 2020, buying an estimated $290K and bringing the position to 7,658 shares worth $746K. The position accounts for 0.52% of the portfolio, ranked #66.

PA Capital first reported a position in RETA in Q4 2018 and has held it in 8 quarters since. The position peaked at $844K in Q1 2019. 186 funds tracked by Wall St. Rank hold RETA as of Q3 2020.

PA Capital held 7,658 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $746K as of Q3 2020.
PA Capital bought 2,322 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2020, an estimated $290K.
Reata Pharmaceuticals, Inc. Class A Common Stock made up 0.52% of PA Capital's portfolio in Q3 2020, its #66 holding.
PA Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and has held it in 8 quarters since.
PA Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $844K in Q1 2019.
186 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.